Pharmaceutical company Boehringer Ingelheim has purchased IDBS’ predictive modelling technology PredictionBase for use at its Biberach an der Riss research site.
Scientists at the Biberach facility, where research into diseases of the central nervous system (CNS), metabolic diseases and respiratory diseases is centred, will use PredictionBase to build and deploy and distribute predictive ADME QSAR models using existing data.
Boehringer Ingelheim sought a solution that would help reduce the effort required for scientists to perform prediction manually, while also efficiently distributing valuable drug discovery knowledge throughout the company.
PredictionBase provided the required predictive technology to integrate with existing Boehringer Ingelheim IT tools to form an automated workflow, allowing scientists to save time by prioritising work, so improving efficiency.
